{"organizations": [], "uuid": "2d3de6ed271f05f95bbcf3eb156322315dfee8b2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 3, "shares": 3, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180205.html", "section_title": "Archive News &amp; Video for Monday, 05 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/bristol-myers-results/bristol-myers-says-key-trial-for-lung-cancer-drug-succeeds-idUSL4N1PV46J", "country": "US", "domain_rank": 408, "title": "Bristol-Myers says key trial for lung cancer drug succeeds", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.055, "site_type": "news", "published": "2018-02-05T20:12:00.000+02:00", "replies_count": 0, "uuid": "2d3de6ed271f05f95bbcf3eb156322315dfee8b2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/bristol-myers-results/bristol-myers-says-key-trial-for-lung-cancer-drug-succeeds-idUSL4N1PV46J", "ord_in_thread": 0, "title": "Bristol-Myers says key trial for lung cancer drug succeeds", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "martina d'couto", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}, {"name": "opdivo", "sentiment": "none"}], "organizations": [{"name": "reuters) - bristol-myers squibb co", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 5 (Reuters) - Bristol-Myers Squibb Co reported a quarterly loss due to a charge it took related to recent U.S. tax law changes, and said a late-stage trial testing its immunotherapy Opdivo in patients with a common type of lung cancer met its main goal.\nFourth-quarter net loss attributable came in at $2.33 billion compared with a year-ago profit of $894 million, as the drugmaker took a $2.9 billion charge.\nBristol-Myers in October said it expects to have final data in the first half of 2018 from a key trial of Opdivo as a treatment for newly diagnosed lung cancer patients.\nReporting by Manas Mishra in Bengaluru; Editing by Martina D'Couto\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-05T20:12:00.000+02:00", "crawled": "2018-02-07T00:01:22.024+02:00", "highlightTitle": ""}